Skip to Content
Merck

[Clofibrate treatment of hyperlipoproteinemia].

Nihon rinsho. Japanese journal of clinical medicine (1994-12-01)
S Oikawa, H Midorikawa
ABSTRACT

Clofibrate has cholesterol- and triglyceride-lowering effect. They affect on the various points in the metabolic pathway of lipoproteins. They improve VLDL-synthesis in liver and increase the activity of LPL and hepatic TG lipase. As the results, HDL-cholesterol increases and LDL decreases. Therefore Clofibrate decreases not only plasma triglyceride but cholesterol levels. It has been reported that Clofibrate have a preventive effect on cardiovascular disease. So these agents are useful in the treatment for hyperlipidemic patients with or without atherosclerosis.

MATERIALS
Product Number
Brand
Product Description

Supelco
Clofibrate, analytical standard
Clofibrate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Clofibrate, liquid